Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. 1H NMR spectroscopy and SEC traces to validate SEC wt % measurement.
  • Fig. S2. SEC traces of polymers from the initial copolymer library synthesis.
  • Fig. S3. Aqueous SEC elution profile for commercial Humalog and UFAL formulations.
  • Fig. S4. SEC traces of copolymers from the second screen targeting DP50.
  • Fig. S5. In vitro and in vivo formulation bioactivity.
  • Fig. S6. Cytotoxicity of leading AC/DC excipient MORPH-NIP23% using NIH/3T3 cells.
  • Fig. S7. Biocompatibility in diabetic rats.
  • Fig. S8. Blood glucose of monomeric insulin in diabetic pigs.
  • Fig. S9. AUMC/AUC for UFAL and Humalog in diabetic pigs.
  • Fig. S10. Pharmacokinetic outputs from model fitting compared to experimental pharmacokinetic data for Humalog and UFAL in diabetic pigs.
  • Table S1. Demonstration of work to validate SEC wt % measurement.
  • Table S2. SEC and MALS characterization and analysis of polymers synthesized in initial AC/DC library.
  • Table S3. Days until aggregation for recombinant insulin formulated with AC/DC excipients at two excipient concentrations (1 and 10 mg/ml).
  • Table S4. SEC and 1H NMR analysis of polymers synthesized during the second screen targeting DP50.
  • Table S5. Days until aggregation for UFAL formulated with AC/DC excipients at 0.1 mg/ml.
  • Table S6. Rate constants used for modeling PK curves in the manuscript.
  • Reference (51)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: